{"source_content":"http://www.huajinsc.cn/1/21请务必阅读正文之后的免责条款部分2021年05月11日行业研究●证券研究报告医药行业动态分析2020年年报&2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼投资要点◆2020年业绩逐季恢复，2021Q1业绩亮眼：2020年医药板块整体营收同比增长6.56%，归母净利润同比增长30.27%。2020Q1受到疫情影响，疫情收益板块表现较好，但由于医院门诊、手术人次大幅下滑，大部分板块的收入和利润均出现不同程度下滑。二季度以来国内疫情得到有效控制，医院门诊手术逐步恢复，医疗需求延迟释放，进而带动医药行业营收和利润增速改善，带动板块业绩进一步增长，利润端增速显著高于营收端。2021Q1医药板块整体营收同比增长30.39%，归母净利润同比增长81.9%，受到去年一季度低基数影响，板块整体表现较好，疫情影响消退后医药板块常规业务回暖明显。◆子行业继续分化，生物制品、医疗器械、医疗服务等Q1表现亮眼：1）生物制品：血制品供需端均受疫情影响，涨价预期仍存在；疫苗在疫情下仍保持较高景气度，预计随着新冠疫苗接种持续推进，将为板块显著贡献业绩。2）医疗器械：板块疫情收益明显，IVD、生命维持类设备需求激增，子版块间分化加剧。短期高性价比的国产企业将直接受益于本次医疗新基建，包括IVD、生命维持设备等企业。3）医疗服务：分化较大，其中服务性医疗机构在上半年受到较大影响，下半年随着疫情控制，总体恢复良好；CRO板块受益于疫情带来的海外订单转移和国内创新药行业高热度，保持高增速；ICL板块完全收益于新冠疫情带来的核酸检测量上升。4）化学制剂：2020年受到疫情影响较大，随着疫情逐步控制，板块业绩出现复苏。5）医药商业：流通企业业务恢复正常；零售药房受到抗疫产品销售波动影响，增速有所放缓，今年预计呈现前低后高态势。6）原料药：去年上半年原料药价格受疫情影响提升，板块总体表现平稳。短期来看，受印度疫情影响，相关原料药的出口有望提振。7）中药：在医保目录控费的大背景下，板块仍有较大压力。◆投资建议：根据医药生物板块年报一季报超预期表现，我们继续看好医药生物板块“创新+消费+疫苗”投资机会。1）创新产业链仍处于景气度上行周期，建议关注创新药及其产业链上CRO、CDMO企业以及高端医疗器械进口替代，重点关注恒瑞医药、药明康德、泰格医药、凯莱英、迈瑞医疗、安图生物、心脉医疗。2）消费板块不受医保控费影响，建议关注医疗服务领域，重点关注爱尔眼科、通策医疗。3）疫苗批签发和销售量均持续提升，新冠疫苗有望在二季度以后做出业绩贡献；重点关注智飞生物、华兰生物、康泰生物。◆风险提示：疫情变化超预期；病毒变异导致疫苗保护效力下降；医药行业政策不确定性；板块内个股业绩低于预期投资评级同步大市-A维持首选股票评级300760迈瑞医疗买入-A300122智飞生物买入-A300601康泰生物增持-A603520司太立买入-B000661长春高新增持-A603259药明康德买入-B一年行业表现资料来源：贝格数据升幅%1M3M12M相对收益5.045.184.54绝对收益4.19-8.8530.60分析师魏赟SAC执业证书编号：S0910521040001weiyun@huajinsc.cn02120377191分析师王睿SAC执业证书编号：S0910519080003wangrui@huajinsc.cn021-20377036报告联系人徐梓煜xuziyu@huajinsc.cn02120377063相关报告医药：专利豁免影响有限，建议关注疫苗调整后机会2021-05-10医药：海外疫情发酵，关注2021-05-06医药：业绩披露进入尾声，关注业绩表现和海外疫情发展2021-04-26医药：药品耗材集采方案推进，把握优质公司调整机会2021-04-19医药：把握业绩窗口期机会，看好业绩确定性强公司2021-04-12-3%4%11%18%25%32%39%46%2020!-052020!-092021!-01沪深300医药行业动态分析http://www.huajinsc.cn/2/21请务必阅读正文之后的免责条款部分内容目录一、2020年业绩逐季恢复，2021Q1业绩亮眼..................................................................................................4（一）业绩逐季恢复，2021Q1业绩表现突出..............................................................................................4（二）研发费用继续攀升，期间费用有所下降............................................................................................4二、子行业：继续分化，生物制品、医疗器械、医疗服务等Q1表现亮眼.........................................................6（一）化学原料药：长期看好特色原料药，印度疫情有望带动订单转移....................................................6（二）化学制剂：业绩修复，创新药仍处于景气度上行周期......................................................................7（三）生物制品：2021Q1增速亮眼，生长激素、疫苗等景气度提振明显....................................................8（四）中药：板块整体仍有压力，看好具有品牌价值的公司....................................................................10（五）医药商业：流通恢复良好，零售药房受抗疫产品销售波动.............................................................11（六）医疗器械：板块受益于疫情，业绩高增速，保持长期看好.............................................................13（七）医疗服务：医疗服务下半年恢复良好，CRO持续高速增长..............................................................15三、投资建议...................................................................................................................................................19四、风险提示...................................................................................................................................................19图表目录图1：行业整体毛利率情况(%)...........................................................................................................................5图2：行业分季度毛利率和净利率情况（%）....................................................................................................5图3：研发支出总额占营业收入比例（%）........................................................................................................5图4：各细分子行业研发支出总额占营业收入比例（%）..................................................................................5图5：行业整体期间费用率(%)...........................................................................................................................6图6：行业整体分季度期间费用率(%)................................................................................................................6图7：原料药板块分季度业绩变动率情况（%）................................................................................................7图8：原料药板块毛利率净利率（%）...............................................................................................................7图9：原料药板块期间费用率（%）..................................................................................................................7图10：化学制剂总营收及净利润增长率（%）..................................................................................................8图11：化学制剂分季度业绩变动率情况（%）..................................................................................................8图12：化学制剂板块毛利率净利率（%）.........................................................................................................8图13：化学制剂板块期间费用率（%）.............................................................................................................8图14：生物制品总营收及净利润增长率（%）..................................................................................................9图15：生物制品分季度业绩变动率情况（%）..................................................................................................9图16：生物制品板块毛利率净利率（%）.........................................................................................................9图17：生物制品板块期间费用率（%）.............................................................................................................9图18：中药总营收及净利润增长率（%）.......................................................................................................11图19：中药分季度业绩变动率情况（%）.......................................................................................................11图20：中药板块毛利率净利率（%）..............................................................................................................11图21：中药板块期间费用率（%）..................................................................................................................11图22：医药流通总营收及净利润增长率（%）................................................................................................12图23：医药流通分季度业绩变动率情况（%）................................................................................................12图24：医药流通板块毛利率净利率（%）.......................................................................................................12图25：医药流通板块期间费用率（%）...........................................................................................................12图26：医疗器械总营收及总归母净利润增长率（%）.....................................................................................13图27：医疗器械板块分季度业绩变动率情况（%）.........................................................................................13行业动态分析http://www.huajinsc.cn/3/21请务必阅读正文之后的免责条款部分图28：医疗器械板块毛利率净利率（%）.......................................................................................................14图29：医疗器械板块期间费用率（%）...........................................................................................................14图30：医疗服务板块分季度业绩变动率情况（%）.........................................................................................16图31：医疗服务板块毛利率净利率有所下滑（%）.........................................................................................16图32：医疗服务板块期间费用率保持平稳（%）............................................................................................16表1：医药行业整体及细分子行业业绩增速对比（%）......................................................................................4表2：血制品财务比率.....................................................................................................................................10表3：疫苗板块财务比率..................................................................................................................................10表4：药店板块财务指标..................................................................................................................................13表5：IVD板块财务指标..................................................................................................................................14表6：耗材财务指标.........................................................................................................................................15表7：医疗设备板块财务指标...........................................................................................................................15表8：医疗机构板块财务指标...........................................................................................................................17表9：CRO板块财务指标................................................................................................................................17表10：ICL板块财务指标................................................................................................................................18行业动态分析http://www.huajinsc.cn/4/21请务必阅读正文之后的免责条款部分一、2020年业绩逐季恢复，2021Q1业绩亮眼（一）业绩逐季恢复，2021Q1业绩表现突出2020年医药板块整体营收同比增长6.56%，归母净利润同比增长30.27%。2020Q1受到疫情影响，疫情收益板块表现较好，但由于医院门诊、手术人次大幅下滑，大部分板块的收入和利润均出现不同程度下滑。二季度以来国内疫情得到有效控制，医院门诊手术逐步恢复，医疗需求延迟释放，进而带动医药行业营收和利润增速改善，带动板块业绩进一步增长，利润端增速显著高于营收端。2021Q1医药板块整体营收同比增长30.39%，归母净利润同比增长81.9%，受到去年一季度低基数影响，板块整体表现较好，疫情影响消退后医药板块常规业务回暖明显。表1：医药行业整体及细分子行业业绩增速对比（%）营收同比增长率（%）归母净利润同比增长率（%）板块20172018201920202021Q120172018201920202021Q1医药整体15.73%19.64%12.74%6.56%30.39%19.13%-13.57%-9.91%30.27%81.90%原料药36.06%25.53%9.26%5.34%26.37%15.16%-5.78%53.15%19.91%17.02%化学制剂13.22%22.95%10.24%-6.06%15.45%46.70%-39.54%-23.38%14.33%22.15%中药11.13%19.48%12.04%-2.61%20.02%7.96%1.07%-11.51%11.20%19.37%生物制品19.91%28.40%14.69%5.94%39.60%15.19%-39.72%45.19%23.93%89.81%医药商业14.10%17.91%15.84%8.46%24.70%21.94%9.19%-7.07%7.38%39.11%医疗器械24.04%20.49%14.15%55.47%102.28%14.12%27.00%10.82%178.20%286.23%医疗服务37.27%19.58%11.53%14.68%74.74%-11.08%75.93%-118.46%964.51%1512.92%资料来源：WIND，华金证券研究所子行业继续分化，利润端看尽管受到疫情干扰，2020年创新药、生物制品、药店、CRO、疫苗、医疗器械、医疗服务等增速表现仍亮眼，仿制药、医药分销等增速相对疲软。（二）研发费用继续攀升，期间费用有所下降从毛利率和净利率水平看，2020年医药整体毛利率34.7%，同比略微上升0.65个百分点；2021Q1毛利率34.94%，环比稳定。2020年医药整体净利率7.45%，同比增长1.3个百分点，2021Q1净利率11.3%。行业动态分析http://www.huajinsc.cn/5/21请务必阅读正文之后的免责条款部分图1：行业整体毛利率情况(%)图2：行业分季度毛利率和净利率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所医药板块2020年研发支出合计689.5亿元，同比增长29.95%，其中化学制剂板块研发支出最高，2020研发支出合计246.89亿元，同比增长19.58%，创新药研发投入持续加大；生物制品板块研发支出增速最快且占营收比重最高，2020年研发支出138.84亿元，同比增长91.32%，主要由于疫苗板块公司新冠疫苗研发有较大投入所致；医疗器械研发支出也不遑多让，2020年研发支出125.64亿元，高端创新器械研发如火如荼。2021Q1研发投入合计153.87亿元，化学制剂板块研发支出52.68亿元，占比超三分之一；生物制品板块研发支出29.13亿元；医疗器械研发支出32.28亿元。图3：研发支出总额占营业收入比例（%）图4：各细分子行业研发支出总额占营业收入比例（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所2020年医药板块销售费用率14.8%，同比下降1.67个百分点；管理费用率5.13%，同比上升0.13%；财务费用率1.2%，同比上升0.01个百分点。2020Q1销售费用率14.1%，同比下降1.04个百分点；管理费用率5.79%，同比下降0.41个百分点；财务费用率1.28%，同比下降0.31个百分点。2020年受到疫情影响，多企业线下营销活动停滞，转移到线上，因此销售费用率有较明显下降，预计今年随着疫情控制得当，销售费用率将略有上升。0%5%10%15%20%25%30%35%40%2015201620172018201920202021Q1毛利率（%）净利率（%）-5%0%5%10%15%20%25%30%35%40%毛利率（%）净利率（%）0.0%0.5%1.0%1.5%2.0%2.5%3.0%3.5%4.0%2015201620172018201920202021Q10%2%4%6%8%10%12%医药整体原料药化学制剂中药生物制品医药商业医疗器械医疗服务201920202021Q1行业动态分析http://www.huajinsc.cn/6/21请务必阅读正文之后的免责条款部分图5：行业整体期间费用率(%)图6：行业整体分季度期间费用率(%)资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所二、子行业：继续分化，生物制品、医疗器械、医疗服务等Q1表现亮眼（一）化学原料药：长期看好特色原料药，印度疫情有望带动订单转移化学原料药板块2020年营业收入同比增长5.34%，归母净利润同比增长19.91%，扣非净利润同比增长25.15%。2021Q1原料药板块营业收入同比增长26.37%，归母净利润同比增长17.02%；对比2019Q1营收和净利润年复合增长率分别为9.62%和12.55%。因为去年上半年原料药价格受疫情影响而提升，抵消了一部分疫情对业绩的影响，原料药板块总体表现平稳。印度疫情爆发，原料药订单有望向中国转移。印度是全球制药产业链中的重要一环，原料药供应全球第三。印度国内疫情严重爆发，且疫情严重地区集中在经济发达地区。为了缓解疫情，印度已有约9个邦和1个中央直辖区发布严格的封禁措施，其中包括马哈拉施特拉邦、北方邦等印度制药产业密集的地区。印度原料药企业停工导致全球原料药供应不足，中国原料药企业有望直接受益。短期来看，因为需求激增，日前印度政府暂停扑热息痛等疫情相关原料药的出口。我国抗生素类和抗病毒类原料药产业相对成熟，有望短期内带动相关原料药的出口。受到印度开工率下降的影响，中间体出口占比较大的企业短期将承压。中长期看，原料药和制剂工厂的开工率会降低，可能导致原料药供给的短期缺口；并且生产成本、运输成本、运输效率等均会受到较大影响，欧美制药企业考虑到顺利生产和成本控制等因素，有望将部分原料药订单转移至国内。通过海外GMP认证的企业出口量有望加大出口，建议关注拥有欧美GMP认证的抗生素、抗病毒类、甾体类原料药相关企业。长期来看，随着国内一致性评价、集中采购等政策的公布，制剂企业集中提升趋势明显，对上游原料药的质量和成本要求提升，行业集中度进一步提升。特色原料药凭借技术壁垒，一体化0%2%4%6%8%10%12%14%16%18%2015201620172018201920202021Q1销售费用率（%）管理费用率（%）财务费用率（%）0%2%4%6%8%10%12%14%16%18%20%销售费用率（%）管理费用率（%）财务费用率（%）行业动态分析http://www.huajinsc.cn/7/21请务必阅读正文之后的免责条款部分等优势，盈利能力将进一步提升。我们看好：1）赛道优质的特色原料药企业；2）具有原料药制剂一体化的特色原料药企业；3）向CMO/CDMO转型的原料药企业。图7：原料药板块总营收及净利润增长率（%）图7：原料药板块分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所原料药板块2020年毛利率提升2.23pct至36.43%，主要因为2020年原料药价格上升；2020年下半年开始价格略微回落，2021Q1毛利率为35.93%。由于行业整体结构改善，加上特色原料药、一体化企业的带动，净利率水平改善，2020年原料药板块净利率提升1.83pct至15.3%，2021Q1净利率再微增加0.16pct。期间费用方面，原料药企业总体费用率水平保持稳定，低于医药行业平均。图8：原料药板块毛利率净利率（%）图9：原料药板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所（二）化学制剂：业绩修复，创新药仍处于景气度上行周期化学制剂板块2020年营收同比下滑6.06%，归母净利润同比增长14.33%，扣非后归母净利润同比增长10.28%。2020Q1化学制剂板块营业收入同比增长15.45%，归母净利润同比增长22.15%。2020年受到疫情影响，上半年住院、手术、门诊用药受到疫情的影响较大，随着疫情逐步控制，影响消退，2020Q2以来医院门诊和手术的逐渐恢复，板块业绩出现复苏。2021Q1由于低基数效应，收入和净利润均有较好增速。预计全年板块仍将保持较好增长态势。-10%0%10%20%30%40%50%60%70%2015201620172018201920202021Q1营业总收入增长率归母净利润增长率扣非后归母净利润增长率-200%-150%-100%-50%0%50%100%150%200%250%300%营业收入增长率归母净利润增长率0%5%10%15%20%25%30%35%40%45%50%2015201720192021Q1毛利率净利率-2%0%2%4%6%8%10%12%14%2015201620172018201920202021Q1销售费用率管理费用率财务费用率行业动态分析http://www.huajinsc.cn/8/21请务必阅读正文之后的免责条款部分长期看，化学制剂板块内部分化仍将持续，创新药公司疫情下仍保持稳定的增长势头，优质创新药仍处于景气度上行周期。疫情带来的医保支出的增大将给用药支出带来更大压力，预计随着带量采购的扩面持续推进，仿制药企业的业绩将持续承压。原料药制剂一体化公司凭借成本优势在竞争中将获得优势地位。此外特色细分制剂龙头如核药、造影剂等企业仍将保持较快的增长速度。图10：化学制剂总营收及净利润增长率（%）图11：化学制剂分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所化学制剂板块2020年毛利率为53.77%，同比下降0.68个百分点；销售费用率28.14%，同比下降1.55个百分点；管理费用率7.81%，同比提升0.9个百分点；财务费用率1.7%，同比提升0.24个百分点。2021Q1板块毛利率53.48%，销售费用率27.55%，管理费用率6.86%，财务费用率1.13%。由于疫情影响，板块线下营销活动受限，叠加带量采购以来销售费用的下降，板块整体销售费用率下降明显。目前线上营销模式已经成为常态，预计未来销售费用率将维持一季度较低水平。图12：化学制剂板块毛利率净利率（%）图13：化学制剂板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所（三）生物制品：2021Q1增速亮眼，生长激素、疫苗等景气度提振明显-50%-40%-30%-20%-10%0%10%20%30%40%50%60%2015201620172018201920202021Q1营业总收入增长率（%）归母净利润增长率（%）-160%-140%-120%-100%-80%-60%-40%-20%0%20%40%60%2018Q12018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1营收增速（%）归母净利润增速（%）0%10%20%30%40%50%60%70%2015201620172018201920202021Q1毛利率（%）净利率（%）0%5%10%15%20%25%30%35%2015201620172018201920202021Q1销售费用率（%）管理费用率（%）财务费用率（%）行业动态分析http://www.huajinsc.cn/9/21请务必阅读正文之后的免责条款部分2020年生物制品板块营收增长率5.94%，同比下滑8.75个百分点；归母净利润增长率23.93%，同比下降21.26个百分点；扣非后归母净利润增长率8.25%。2021Q1生物制品板块营业收入同比增长39.6%，归母净利润同比增长89.81%。2020年生物制品板块整体营收受疫情影响，但随着疫情负面影响逐步消退，医院门诊量和住院量逐步恢复，20Q2-4业绩出现恢复性增长，2021Q1增速亮眼，生长激素、疫苗等景气度提振明显，这些细分子行业不在医保范围内，政策免疫性高，未来有望持续保持向上势头。图14：生物制品总营收及净利润增长率（%）图15：生物制品分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所生物制品板块2020年毛利率为56.74%，同比上升1.85个百分点；销售费用率23.03%，同比下降2.14个百分点；管理费用率7.91%，同比上升0.96个百分点；财务费用率1.1%，同比下降0.31个百分点。2020Q1板块毛利率56.05%，销售费用率20.42%，管理费用率7.28%，财务费用率0.63%。图16：生物制品板块毛利率净利率（%）图17：生物制品板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所血制品：供需端均受疫情影响，涨价预期仍存在受疫情影响，静丙需求较好销售旺盛，但企业受库存影响也对发货进行了一定的控制。其他品种由于医院门诊和手术量的下降有所承压，血制品2020Q1总体表现略有下滑，2020Q2后，随着疫情控制及诊疗恢复，白蛋白需求回暖明显，静丙需求下滑。供给端来看，2020年全年采浆下降8%左右，给2020及2021Q1供给造成一定影响。进口白蛋白Q1开始下滑明显，预计-60%-40%-20%0%20%40%60%80%100%2015201620172018201920202021Q1营业总收入增长率（%）归母净利润增长率（%）-40%-20%0%20%40%60%80%100%2018Q12018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1营收增速（%）归母净利润增速（%）0%10%20%30%40%50%60%70%2015201620172018201920202021Q1毛利率（%）净利率（%）0%5%10%15%20%25%30%35%2015201620172018201920202021Q1销售费用率（%）管理费用率（%）财务费用率（%）行业动态分析http://www.huajinsc.cn/10/21请务必阅读正文之后的免责条款部分将产生供需缺口，未来涨价预计仍存在。长期看疫情提升了血制品认知程度，有利于血制品的进一步销售和推广。表2：血制品财务比率2015201620172018201920202021Q1营业总收入增长率（%）15.21%26.92%4.21%25.16%18.92%11.65%6.29%归母净利润增长率59.19%30.83%7.80%-75.13%289.82%29.20%20.46%毛利率（%）55.98%58.70%60.35%58.02%58.23%59.13%53.32%净利率（%）38.16%37.93%38.69%9.53%25.68%29.95%31.86%销售费用率（%）3.64%4.83%10.18%15.50%14.94%16.19%10.59%管理费用率（%）17.83%16.96%14.89%9.06%8.31%7.51%8.39%财务费用率（%）1.49%1.20%0.88%0.52%-0.04%-0.45%-1.01%资料来源：WIND，华金证券研究所疫苗：疫情下疫苗板块仍保持了较高的景气度，尽管疫情影响接种点疫苗接种，但2020Q2以后补接种需求开始集中释放，13价、HPV等重磅疫苗品种批签发顺利；疫情提高了医生和患者对于疫苗的接种意识，冬季像流感疫苗、13价肺炎、23价肺炎、肺结核疫苗等呼吸系统疫苗的接种明显增加，全年疫苗板块业绩表现突出。叠加2020Q1低基数，2021Q1疫苗板块业绩增速亮眼。短期看国内疫苗企业新冠疫苗即将进入业绩兑现期，业绩弹性较大。此外疫苗新产品陆续上市，今明两年，智飞的微卡结核疫苗，康泰的13价肺炎疫苗、人二倍体狂苗，康希诺的四价脑膜炎结合疫苗等重磅产品有望上市贡献业绩，高成长持续。长期来看，新冠疫情提高了国内对于疫苗的重视程度，将有利于疫苗产业技术升级，随着疫苗管理法的出台，疫苗的严监管淘汰小公司的同时也构筑了较高的进入壁垒，疫苗行业技术难度较高，产品获批后放量较快，长期看行业有望迎来新的创新驱动景气周期。新冠疫苗的研发也加快了疫苗行业新技术的开发和应用，加速了疫苗行业的技术迭代升级，更好的平台有望构建更高的技术壁垒，在行业中地位进一步提升。表3：疫苗板块财务比率2015201620172018201920202021Q1营业总收入增长率（%）17.88%-13.59%73.54%120.57%59.19%54.67%81.54%归母净利润增长率-204.59%176.52%-8.13%1099.67%2.45%70.76%123.71%毛利率（%）63.47%73.35%78.36%68.80%55.24%56.26%54.88%净利率（%）-18.69%9.38%5.68%33.70%21.93%24.72%22.96%销售费用率（%）25.79%33.80%35.60%27.26%19.07%18.00%13.95%管理费用率（%）23.91%25.10%15.99%7.02%5.31%3.65%3.90%财务费用率（%）4.53%4.17%2.31%0.53%0.16%0.31%-0.45%资料来源：WIND，华金证券研究所（四）中药：板块整体仍有压力，看好具有品牌价值的公司行业动态分析http://www.huajinsc.cn/11/21请务必阅读正文之后的免责条款部分中药板块业绩增速持续下行，2020年营业总收入同比下滑2.61%，同比下滑14.65个百分点；归母净利润增长率11.2%，同比上升11.2个百分点，扣非后归母净利润增长率8.36%。疫情中一些重要产品作为治疗、预防新冠的产品，得到大范围应用；非疫情品种收到疫情较大影响，但由于全年销售费用的缩减，以及19年本身基数不高，利润端仍呈现增长态势。2020Q1中药板块营业收入增长20.02%，归母净利润增长19.37%。在医保目录控费的大背景下，医保目录调整，辅助用药监控等给中药制剂及中药注射剂公司带来较大压力。对于不受医保控费的的中药消费品来说，经济下行压力对于消费的抑制给予重中药消费产品有一定的负面影响。长期看我们主要看好具有品牌价值的中药公司，能持续享受稀缺标的带来的估值溢价。图18：中药总营收及净利润增长率（%）图19：中药分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所中药板块2020年毛利率为43.39%，同比下降0.99个百分点；销售费用率24.09%，同比下降1.58个百分点；管理费用率5.96%，同比上升0.2个百分点；财务费用率1.2%，同比下降0.17个百分点。2021Q1板块毛利率44.67%，销售费用率23.15%，管理费用率4.88%，财务费用率0.92%。图20：中药板块毛利率净利率（%）图21：中药板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所（五）医药商业：流通恢复良好，零售药房受抗疫产品销售波动-15%-10%-5%0%5%10%15%20%25%2015201620172018201920202021Q1营业总收入增长率（%）归母净利润增长率（%）-120%-100%-80%-60%-40%-20%0%20%40%60%2018Q12018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1营收增速（%）归母净利润增速（%）0%10%20%30%40%50%60%2015201620172018201920202021Q1毛利率（%）净利率（%）0%5%10%15%20%25%30%2015201620172018201920202021Q1销售费用率（%）管理费用率（%）财务费用率（%）行业动态分析http://www.huajinsc.cn/12/21请务必阅读正文之后的免责条款部分医药商业板块2020年营业总收入增速8.46%，同比下滑7.38个百分点；归母净利润增长率7.38%，同比提升14.45个百分点；扣非后归母净利润增长率7.72%，同比增长6.49个百分点。2021Q1流通板块营业收入上升24.7%，归母净利润增长39.11%，高增长主要由于2020Q1低基数效应。短期看，疫情稳定后诊疗人次逐步恢复，交通管制放开，流通企业业务恢复正常；零售药房受到抗疫产品销售波动影响，预计增速有所放缓。长期看，两票制、带量采购等政策持续推进，对于行业集中度持续提升有推动作用，预计未来行业集中度仍将持续提升。图22：医药流通总营收及净利润增长率（%）图23：医药流通分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所医药商业板块2020年毛利率为13.36%，同比下降0.32个百分点；销售费用率6.17%，同比下降0.2个百分点；管理费用率2.3%，同比下降0.03个百分点；财务费用率0.79%，同比下降0.15个百分点。2021Q1板块毛利率12.57%，销售费用率5.96%，管理费用率2.19%，财务费用率0.86%。图24：医药流通板块毛利率净利率（%）图25：医药流通板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所零售药店：抗疫产品销售波动，全年经营预计呈现前低后高趋势零售药店2020年业绩增速保持较高水平主要由于疫情期间药店成为院外重要销售渠道，防疫药品、器械销量增长显著。2021Q1业绩增速放缓一是因为2020Q1的高基数效应，二是因为部分地区感冒等产品政策限制，三是春节就地过年政策影响，四是2020Q1疫情影响并购，2020-10%0%10%20%30%40%50%2015201620172018201920202021Q1营业总收入增长率（%）归母净利润增长率（%）-40%-30%-20%-10%0%10%20%30%40%50%2018Q12018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1营收增速（%）归母净利润增速（%）0%2%4%6%8%10%12%14%16%2015201620172018201920202021Q1毛利率（%）净利率（%）0%1%2%3%4%5%6%7%8%2015201720192021Q1销售费用率（%）管理费用率（%）财务费用率（%）行业动态分析http://www.huajinsc.cn/13/21请务必阅读正文之后的免责条款部分年并购项目下半年开展较多尚未贡献收入利润。整体看在高基数情况下，行业将保持稳定增长，随着去年下半年并购项目逐步贡献业绩，全年经营预计呈现前低后高趋势。长期看，处方外流带来的集中度提升逻辑不变，疫情期间，中小药店经营面临挑战，大型药店受益于疫情，行业集中度进一步趋向提高。互联网O2O业务带动药店增长提速，线上线下差异化竞争，医保端线上对接仍存在困难，短期线上对线下药店冲击不大。表4：药店板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）18.03%22.98%22.22%24.67%26.63%24.91%15.09%归母净利润增长率（%）27.43%16.93%21.92%21.53%24.02%38.20%23.19%毛利率（%）39.81%39.19%39.06%39.09%37.42%35.90%37.41%净利率（%）6.26%5.82%5.72%5.71%5.71%6.38%7.53%销售费用率（%）26.05%26.02%25.72%26.21%25.10%23.17%23.55%管理费用率（%）4.79%4.60%4.62%4.34%4.35%4.35%3.82%财务费用率（%）0.23%0.40%0.49%0.37%0.36%0.17%0.85%资料来源：WIND，华金证券研究所（六）医疗器械：板块受益于疫情，业绩高增速，保持长期看好医疗器械板块2020年营业总收入增速55.47%，归母净利润增长率144.93%，扣非后归母净利润增长率178.20%。2020Q1医疗器械板块营业收入和归母净利润同比增速分别为102.28%和245.15%；对比2019Q1年复合增长率分别为54.59%和99.52%。高增速得益于新冠疫情导致IVD、生命维持类设备需求激增，子版块间分化加剧。短期来看，本次新冠疫情反映出国内基层医院诊疗能力的问题，在疫情后国家推出多个政策支持基层医疗资源的建设，加强基层诊疗能力和针对传染病的疾控医院建设。因为基层医院购买力较低，高性价比的国产企业将直接受益于本次医疗新基建，包括IVD、生命维持设备等企业。中长期来看，国内器械集采的趋势明确，未来国内高技术水平的公司凭借高性价比成本优势，有望进一步实现进口替代，加速市场份额的替换。我们看好在细分赛道中技术实力和综合竞争力强的器材企业。图26：医疗器械总营收及总归母净利润增长率（%）图27：医疗器械板块分季度业绩变动率情况（%）0%50%100%150%200%250%300%350%201620172018201920202021Q1营业总收入增长率归母净利润增长率-1500%-1000%-500%0%500%1000%1500%2000%营业收入增长率归母净利润增长率行业动态分析http://www.huajinsc.cn/14/21请务必阅读正文之后的免责条款部分资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所医疗器械板块2020年毛利率同比增长5.13pct至57.50%，2021年板块毛利率增加2.09pct至59.60%。主要因为高附加值的检测试剂盒、呼吸机等抗疫产品占比增加和行业集中度提升带来的规模效应。费用率方面，2020年板块销售费用率减低4.83pct至13.44%，主要因为疫情期间差旅费用明显下降和收入高增速。管理费用率和财务费用率保持稳定，合计下降1.00pct。受益于毛利提升和期间费用率下降，2020年板块净利率增加9.55pct至25.99%；2021Q1年板块净利率增加至32.36%。图28：医疗器械板块毛利率净利率（%）图29：医疗器械板块期间费用率（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所IVD：常规业务下半年加速恢复，未来看好化学发光和POCTIVD板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%；2021Q1营收和净利润增速分别为83.5%和216.3%。高增速一方面来自疫情相关的核酸检测试剂盒的增量收入，一方面来自常规业务在2020下半年后的快速恢复。短期来看，随着常规业务恢复良好，新冠试剂盒出口仍有疫情业绩支撑。中长期看，随着DRGs、带量采购等政策的推出，IVD试剂盒终端价格将被压缩，利好具备规模效应带来的成本优势和技术实力强的企业，未来行业集中度将提升。本质疫情中分子诊断起到了重要作用，未来有望加速放量。此外，我们看好化学发光和POCT细分子行业，分别对应行业高通量集中化和向科室分散化的两个大趋势。建议关注新产业、迈瑞医疗、安图生物、万孚生物。表5：IVD板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）18.19%24.02%27.05%23.09%15.25%92.92%166.99%归母净利润增长率（%）16.95%24.09%21.24%25.23%8.51%267.01%310.01%扣非后归母净利润增长率（%）0.96%19.93%23.32%11.94%-9.13%302.05%397.22%毛利率（%）59.27%60.61%60.44%57.83%59.65%66.93%69.10%净利率（%）22.90%22.64%19.02%18.59%17.03%33.29%38.68%销售费用率（%）17.58%19.33%19.70%18.72%19.89%15.23%14.28%管理费用率（%）15.17%14.78%15.90%9.82%7.39%5.42%4.46%财务费用率（%）0.02%-0.11%0.59%0.42%0.56%1.09%-0.17%资料来源：wind，华金证券研究所耗材：总体恢复情况好，看好人工晶体、骨科产品、心血管产品等高值耗材0%10%20%30%40%50%60%70%2015201720192021Q1毛利率净利率0%2%4%6%8%10%12%14%16%18%20%2015201620172018201920202021Q1销售费用率管理费用率财务费用率行业动态分析http://www.huajinsc.cn/15/21请务必阅读正文之后的免责条款部分耗材板块2020年营业总收入和归母净利润同比增速分别为35.5%和120.6%；2021Q1营收和净利润增速分别为65.1%和237.0%。眼科、骨科等高值耗材Q1承压，Q2恢复情况良好；口罩、手套等防护类耗材上半年业绩增长快；其他耗材上半年总体受到一定影响。2020上半年受到医院手术量下降影响，相关高值耗材表现不佳，刚需类耗材受影响小；下半年开始随着疫情控制后医院手术量的增加，非刚需手术类耗材挤压需求快速释放。中长期来看，未来随着国内健康意识的提升，人工晶体、骨科产品、心血管产品等高值耗材空间大且需求放量快。未来集中采购将大幅降低终端产品价格，加快相关手术的普及，有利于高水平和高性价比的国产企业加速进口替代。表6：耗材财务指标2015201620172018201920202021Q1营业总收入增长率（%）17.20%19.62%29.61%24.53%31.24%35.54%120.59%归母净利润增长率（%）28.40%11.54%33.45%48.15%29.77%65.05%236.95%扣非后归母净利润增长率（%）22.40%23.24%25.47%26.54%33.88%7.53%298.32%毛利率（%）51.07%58.75%58.86%62.00%64.96%68.15%68.87%净利率（%）20.46%21.98%22.52%26.75%26.25%31.97%38.15%销售费用率（%）13.55%16.53%16.59%19.00%21.15%18.03%15.06%管理费用率（%）11.77%12.04%12.45%10.21%8.66%6.74%5.69%财务费用率（%）0.24%-0.94%0.19%-0.84%-0.72%-0.22%-0.74%资料来源：wind，华金证券研究所设备：板块平稳增长，传染病医院建设直接利好相关企业设备板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%；2021Q1营收和净利润增速分别为83.5%和216.3%。疫情期间呼吸机、监护仪、便携超声、移动DR、CT等设备需求大增，且在海外疫情爆发后出口量增加明显。非抗疫设备在上半年受到医院招标暂缓业绩承压，下半年开始逐渐恢复。短期来看，抗疫设备出口订单保持有序增长，非抗疫设备招标有序进行。中长期看，国家在疫情后开始加强各地传染病医院的建设，对医院中的设备要求做了明确规划，长期利好相关设备公司的发展。表7：医疗设备板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）13.69%13.30%21.89%16.62%11.12%59.47%83.49%归母净利润增长率（%）-8.42%30.62%29.33%30.85%26.15%148.37%216.26%扣非后归母净利润增长率（%）-0.99%10.32%1.97%35.46%14.72%198.79%232.20%毛利率（%）41.98%44.01%45.36%47.52%49.68%54.95%56.50%净利率（%）10.91%12.64%13.30%14.64%16.40%25.91%32.15%销售费用率（%）14.42%15.00%15.06%16.68%17.19%11.29%10.11%管理费用率（%）14.27%13.58%12.49%7.03%6.95%5.08%4.93%财务费用率（%）0.27%0.42%1.65%0.64%0.49%1.30%0.33%资料来源：wind，华金证券研究所（七）医疗服务：医疗服务下半年恢复良好，CRO持续高速增长行业动态分析http://www.huajinsc.cn/16/21请务必阅读正文之后的免责条款部分医疗服务板块2020年营业收入增长14.68%，归母净利润同比增长965%，扣非净利润同比增长392%。高增长主要因为2019年美年健康、宜华健康、创新医疗等公司出现大额亏损，导致2019年基数较低，剔除影响后板块扣非净利润增速为58.75%。随着国内疫情的控制和CRO板块的高景气，2020Q1医疗服务板块保持高增速，总营收和净利润对比2019Q1年复合增长率分别为24.98%和72.92%。医疗服务板块分化较大，其中服务性医疗机构在上半年受到较大影响，下半年随着疫情控制，总体恢复良好；CRO板块受益于疫情带来的海外订单转移和国内创新药行业高热度，保持高增速；ICL板块完全收益于新冠疫情带来的核酸检测量上升。图：医疗服务板块总营收及总归母净利润增长率（%）图30：医疗服务板块分季度业绩变动率情况（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所医疗服务板块2020年毛利率减少0.05pct至38.16%，基本保持平稳；2021Q1毛利率降低2.14个百分点到36.02%。期间费用方面，由于去年总体差旅减少且CRO企业收入增速较高，板块期间费用率合计减低1.17pct。图31：医疗服务板块毛利率净利率有所下滑（%）图32：医疗服务板块期间费用率保持平稳（%）资料来源：WIND，华金证券研究所资料来源：WIND，华金证券研究所服务性医疗机构：下半年开始恢复，基本恢复常态下增速受到疫情的影响，2020上半年服务性医疗机构受到较大影响，直到3月国内疫情开始控制后，就医人数开始逐渐恢复，挤压的就诊需求在4月开始逐渐放量，到下半年基本恢复2019年水平；2020年爱尔眼科、通策医疗、美年健康扣非归母净利润增速分别为49.1%、4.5%、-30.9%。-400%-200%0%200%400%600%800%1000%1200%201520162017201820192020营业总收入增长率归母净利润增长率扣非后归母净利润增长率-50%0%50%100%150%200%250%300%营业收入增长率归母净利润增长率-5%0%5%10%15%20%25%30%35%40%45%2015201720192021Q1毛利率净利率0%2%4%6%8%10%12%14%16%2015201620172018201920202021Q1销售费用率管理费用率财务费用率行业动态分析http://www.huajinsc.cn/17/21请务必阅读正文之后的免责条款部分目前国内疫情稳定，虽然输入性压力仍存在，但对着疫苗接种率提升，大规模爆发可能性小，服务性医疗机构预计将保持稳定增长。表8：医疗机构板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）33.56%46.74%42.29%28.85%11.83%10.22%90.00%归母净利润增长率（%）28.44%174.10%-21.95%-60.04%-385.63%225.64%246.82%扣非后归母净利润增长率（%）5.37%201.89%-27.86%-61.94%-661.97%182.29%250.97%毛利率（%）38.47%37.85%38.49%37.88%36.98%38.81%36.81%净利率（%）6.81%13.21%8.09%3.68%-4.82%8.64%8.34%销售费用率（%）11.87%11.45%11.89%11.54%11.79%11.17%11.08%管理费用率（%）14.15%13.24%12.03%10.18%9.91%8.99%9.50%财务费用率（%）2.30%1.84%2.21%3.12%3.12%2.33%2.28%资料来源：wind，华金证券研究所CRO：疫情带来订单转移，行业保持高景气度CRO企业受益于疫情，二季度由于海外企业纷纷停工，部分CRO订单流入国内，订单明显增加，龙头企业在保证疫情防控的前提下，有序交付订单，板块业保持高速增长；2020年药明康德、昭衍新药、康龙化成扣非归母净利润增速分别为24.6%、88.6%、58.5%。目前CRO公司在手订单普遍充足，2021Q2主要消化订单，预计业绩将延续高增速。新冠疫情是催化剂，加速国内CRO龙头企业的国际化，建立海外品牌形象。欧美CRO订单长期有向印度、中国等高技术水平国家转移的趋势，目前印度疫情再次爆发，短期内预计难以平息，海外订单有望优先向国内转移。此外，随着国内疫情控制，国内医药企业的研发需求恢复良好，未来CRO公司将保持高增速，我们持续看好CRO/CDMO龙头企业泰格医药、康龙化成、药明康德和昭衍新药。表9：CRO板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）24.07%24.99%30.56%31.66%31.98%28.41%53.12%归母净利润增长率（%）0.95%96.70%31.32%78.48%6.77%78.42%248.52%扣非后归母净利润增长率（%）15.75%-32.92%69.05%62.86%30.79%32.60%124.95%毛利率（%）36.03%38.90%40.47%39.29%39.65%39.61%37.95%净利率（%）14.05%16.63%15.78%21.05%17.27%23.95%31.92%销售费用率（%）3.76%3.19%3.35%3.15%3.19%3.14%3.11%管理费用率（%）19.48%17.05%16.30%12.59%12.17%12.05%11.32%财务费用率（%）-0.20%-0.92%2.29%0.75%0.68%2.62%-1.12%资料来源：wind，华金证券研究所ICL：受益于核酸检测增量，常规业务恢复良好，特检业务比例增加ICL企业完全收益于疫情带来的新冠核酸检测需求增加，包括常规检测和大面积核酸检测，因为新冠业务的高毛利，龙头企业净利润保持高增速；2020年金域医学和迪安诊断扣非归母净利润增速分别为357%和172%。行业动态分析http://www.huajinsc.cn/18/21请务必阅读正文之后的免责条款部分新冠业务将成为长期普检业务。2021Q1因为春节跨省核酸检测政策，ICL企业新冠业务保持高增速。从清明和五一假期国家政策来看，未来除了大面积爆发疫情外，未来新冠核酸检测量将大幅下降。目前新冠核酸检测存量市场主要是海关、医院住院等刚需场景，预计未来新冠业务将成为长期的普检业务，为公司提供长期稳定收入。常规业务保持高速恢复，特检是未来发展方向。总体来看，2020上半年ICL企业常规业务受到疫情带来的医院端检测量下降影响较大，到下半年恢复此前收入规模。尤其是伴随肿瘤等重要疾病的刚需特检项目；ICL两大龙头特检业务占比在2020年均实现增长。新冠疫情给ICL行业提供了新契机，带动行业在市场中的认可度；同时未来随着带量采购、DRGs等政策的推行，医院检测外包意愿提升，长期利好ICL行业。此外，新冠核酸检测加速启动了迪安、金域2C业务的布局，为公司提供高毛利收入，优化现金流。我们看好1）拥有强大学术地位和市场影响力的ICL龙头金域医学；2）与医院合作共建精准中心进行深度绑定，且自产产品+ICL+渠道全产业链发展的迪安诊断。表10：ICL板块财务指标2015201620172018201920202021Q1营业总收入增长率（%）29.37%54.88%24.19%28.48%18.09%66.03%111.83%归母净利润增长率（%）156.06%32.84%22.32%9.06%4.51%306.19%634.21%扣非后归母净利润增长率（%）38.01%52.16%10.31%21.38%2.01%385.40%0.00%毛利率（%）11.15%10.36%10.44%9.30%8.15%17.94%21.84%净利率（%）46.65%42.71%42.38%41.19%39.91%48.72%48.55%销售费用率（%）16.94%15.33%14.82%14.25%14.17%11.69%11.14%管理费用率（%）17.17%15.58%15.21%9.10%8.51%7.21%6.64%财务费用率（%）0.82%0.57%1.29%1.23%1.34%1.48%0.53%资料来源：wind，华金证券研究所行业动态分析http://www.huajinsc.cn/19/21请务必阅读正文之后的免责条款部分三、投资建议根据医药生物板块年报一季报超预期表现，我们继续看好医药生物板块“创新+消费+疫苗”投资机会。创新产业链仍处于景气度上行周期，1）在管线中能够做到速度最快或质量最优的产品在竞争中有望顺利脱颖而出，建议关注研发速度和销售布局均处于领先状态的强执行力行业龙头，重点关注恒瑞医药。2）CXO因成本优势和效率优势成为首选，疫情催化海外创新产业链向国内转移进程；此外国内创新药蓬勃也带动CXO高景气。看好产业链完备的大型CRO、CDMO公司以及细分领域具备专业特长的特色CRO企业，建议重点关注药明康德、泰格医药、凯莱英。3）在出口突破和国内进口替代方面有较大空间，主要看好化学发光和医疗设备以及高壁垒强创新的特色高值耗材细分领域，重点关注迈瑞医疗、迈克生物、安图生物、心脉医疗、南微医学。消费板块不受医保控费影响，受益于消费升级，预计医疗服务、医美、生长激素等领域2021年将继续高速增长。1）医疗服务：老龄化趋势加快+医疗保健支付能力的提升持续催生医疗服务领域需求；我国存在医生资源不均的问题，政策持续鼓励民营机构办医；医疗服务疫情后恢复速度较快，今年预计业绩表现突出，重点关注爱尔眼科、通策医疗。2）生长激素：其消费属性较强，市场空间不断扩大；去年收到疫情影响较大，随着疫情影响减弱，高增长有望恢复，重点关注长春高新。疫苗批签发和销售量均持续提升，业绩高增可期。创新疫苗陆续上市，驱动国内疫苗市场高速扩容。叠加新冠疫苗国内研发上市全球领先，有望在二季度以后做出业绩贡献。重点关注智飞生物、华兰生物、康泰生物。四、风险提示疫情变化超预期；病毒变异导致疫苗保护效力下降；医药行业政策不确定性；板块内个股业绩低于预期行业动态分析http://www.huajinsc.cn/20/21请务必阅读正文之后的免责条款部分行业评级体系收益评级：领先大市—未来6个月的投资收益率领先沪深300指数10%以上；同步大市—未来6个月的投资收益率与沪深300指数的变动幅度相差-10%至10%；落后大市—未来6个月的投资收益率落后沪深300指数10%以上；风险评级：A—正常风险，未来6个月投资收益率的波动小于等于沪深300指数波动；B—较高风险，未来6个月投资收益率的波动大于沪深300指数波动；分析师声明魏赟、王睿声明，本人具有中国证券业协会授予的证券投资咨询执业资格，勤勉尽责、诚实守信。本人对本报告的内容和观点负责，保证信息来源合法合规、研究方法专业审慎、研究观点独立公正、分析结论具有合理依据，特此声明。行业动态分析http://www.huajinsc.cn/21/21请务必阅读正文之后的免责条款部分本公司具备证券投资咨询业务资格的说明华金证券股份有限公司（以下简称“本公司”）经中国证券监督管理委员会核准，取得证券投资咨询业务许可。本公司及其投资咨询人员可以为证券投资人或客户提供证券投资分析、预测或者建议等直接或间接的有偿咨询服务。发布证券研究报告，是证券投资咨询业务的一种基本形式，本公司可以对证券及证券相关产品的价值、市场走势或者相关影响因素进行分析，形成证券估值、投资评级等投资分析意见，制作证券研究报告，并向本公司的客户发布。免责声明：本报告仅供华金证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因为任何机构或个人接收到本报告而视其为本公司的当然客户。本报告基于已公开的资料或信息撰写，但本公司不保证该等信息及资料的完整性、准确性。本报告所载的信息、资料、建议及推测仅反映本公司于本报告发布当日的判断，本报告中的证券或投资标的价格、价值及投资带来的收入可能会波动。在不同时期，本公司可能撰写并发布与本报告所载资料、建议及推测不一致的报告。本公司不保证本报告所含信息及资料保持在最新状态，本公司将随时补充、更新和修订有关信息及资料，但不保证及时公开发布。同时，本公司有权对本报告所含信息在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。任何有关本报告的摘要或节选都不代表本报告正式完整的观点，一切须以本公司向客户发布的本报告完整版本为准，如有需要，客户可以向本公司投资顾问进一步咨询。在法律许可的情况下，本公司及所属关联机构可能会持有报告中提到的公司所发行的证券或期权并进行证券或期权交易，也可能为这些公司提供或者争取提供投资银行、财务顾问或者金融产品等相关服务，提请客户充分注意。客户不应将本报告为作出其投资决策的惟一参考因素，亦不应认为本报告可以取代客户自身的投资判断与决策。在任何情况下，本报告中的信息或所表述的意见均不构成对任何人的投资建议，无论是否已经明示或暗示，本报告不能作为道义的、责任的和法律的依据或者凭证。在任何情况下，本公司亦不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。本报告版权仅为本公司所有，未经事先书面许可，任何机构和个人不得以任何形式翻版、复制、发表、转发、篡改或引用本报告的任何部分。如征得本公司同意进行引用、刊发的，需在允许的范围内使用，并注明出处为“华金证券股份有限公司研究所”，且不得对本报告进行任何有悖原意的引用、删节和修改。华金证券股份有限公司对本声明条款具有惟一修改权和最终解释权。风险提示:报告中的内容和意见仅供参考，并不构成对所述证券买卖的出价或询价。投资者对其投资行为负完全责任，我公司及其雇员对使用本报告及其内容所引发的任何直接或间接损失概不负责。华金证券股份有限公司地址：上海市浦东新区杨高南路759号（陆家嘴世纪金融广场）31层电话：021-20655588网址：www.huajinsc.cn","data":[{"id":"1","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年医药板块整体营收同比增长6.56%","content_offset":["139","161"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["6.56%","156","161"],"indicator_element":{"时间":["2020年","139","144"],"行业":["医药","144","146"],"区域":["国内","245","247"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长30.27%","content_offset":["162","177"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["30.27%","171","177"],"indicator_element":{"时间":["2020年","73","78"],"行业":["医药","65","67"],"区域":["国内","245","247"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1医药板块整体营收同比增长30.39%","content_offset":["319","343"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["30.39%","337","343"],"indicator_element":{"时间":["2021Q1","319","325"],"行业":["医药","325","327"],"区域":["国内","245","247"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长81.9%","content_offset":["344","358"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["81.9%","353","358"],"indicator_element":{"时间":["2021Q1","319","325"],"行业":["医药","280","282"],"区域":["国内","245","247"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年医药整体毛利率34.7%","content_offset":["9623","9640"],"indicators":[{"indicator_name":"毛利率","indicator_value":["34.7%","9635","9640"],"indicator_element":{"时间":["2020年","9623","9628"],"行业":["医药","9628","9630"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比略微上升0.65个百分点","content_offset":["9641","9655"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["0.65个百分点","9647","9655"],"indicator_element":{"时间":["2020年","9623","9628"],"行业":["医药","9579","9581"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1毛利率34.94%","content_offset":["9656","9671"],"indicators":[{"indicator_name":"毛利率","indicator_value":["34.94%","9665","9671"],"indicator_element":{"时间":["2021Q1","9656","9662"],"行业":["医药","9579","9581"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"环比稳定","content_offset":["9672","9676"],"indicators":[{"indicator_name":"毛利率环比","indicator_value":["稳定","9674","9676"],"indicator_element":{"时间":["2021Q1","9656","9662"],"行业":["医药","9579","9581"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年医药整体净利率7.45%","content_offset":["9677","9694"],"indicators":[{"indicator_name":"净利率","indicator_value":["7.45%","9689","9694"],"indicator_element":{"时间":["2020年","9677","9682"],"行业":["医药","9682","9684"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比增长1.3个百分点","content_offset":["9695","9706"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["1.3个百分点","9699","9706"],"indicator_element":{"时间":["2020年","9623","9628"],"行业":["医药","9628","9630"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1净利率11.3%","content_offset":["9707","9721"],"indicators":[{"indicator_name":"净利率","indicator_value":["11.3%","9716","9721"],"indicator_element":{"时间":["2021Q1","9707","9713"],"行业":["医药","9628","9630"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医药板块2020年研发支出合计689.5亿元","content_offset":["9840","9862"],"indicators":[{"indicator_name":"研发费用","indicator_value":["689.5亿元","9855","9862"],"indicator_element":{"时间":["2020年","9844","9849"],"行业":["医药","9840","9842"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比增长29.95%","content_offset":["9863","9873"],"indicators":[{"indicator_name":"研发费用同比","indicator_value":["29.95%","9867","9873"],"indicator_element":{"时间":["2020年","9844","9849"],"行业":["医药","9840","9842"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"其中化学制剂板块研发支出最高，2020研发支出合计246.89亿元","content_offset":["9874","9907"],"indicators":[{"indicator_name":"研发费用","indicator_value":["246.89亿元","9899","9907"],"indicator_element":{"时间":["2020年","9844","9849"],"行业":["化学制剂","9876","9880"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比增长19.58%","content_offset":["9908","9918"],"indicators":[{"indicator_name":"研发费用同比","indicator_value":["19.58%","9912","9918"],"indicator_element":{"时间":["2020年","9844","9849"],"行业":["化学制剂","9876","9880"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年研发支出138.84亿元","content_offset":["9954","9971"],"indicators":[{"indicator_name":"研发费用","indicator_value":["138.84亿元","9963","9971"],"indicator_element":{"时间":["2020年","9954","9959"],"行业":["生物制品","9931","9935"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比增长91.32%","content_offset":["9972","9982"],"indicators":[{"indicator_name":"研发费用同比","indicator_value":["91.32%","9976","9982"],"indicator_element":{"时间":["2020年","9954","9959"],"行业":["生物制品","9931","9935"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1研发投入合计153.87亿元","content_offset":["10052","10072"],"indicators":[{"indicator_name":"研发费用","indicator_value":["153.87亿元","10064","10072"],"indicator_element":{"时间":["2021Q1","10052","10058"],"行业":["医疗","10007","10009"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"化学制剂板块研发支出52.68亿元","content_offset":["10073","10090"],"indicators":[{"indicator_name":"研发费用","indicator_value":["52.68亿元","10083","10090"],"indicator_element":{"时间":["2021Q1","10052","10058"],"行业":["化学制剂","10073","10077"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"占比超三分之一","content_offset":["10091","10098"],"indicators":[{"indicator_name":"研发费用占比","indicator_value":["超三分之一","10093","10098"],"indicator_element":{"时间":["2021Q1","10052","10058"],"行业":["化学制剂","10073","10077"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"生物制品板块研发支出29.13亿元","content_offset":["10099","10116"],"indicators":[{"indicator_name":"研发费用","indicator_value":["29.13亿元","10109","10116"],"indicator_element":{"时间":["2021Q1","10052","10058"],"行业":["生物制品","10099","10103"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"化学原料药板块2020年营业收入同比增长5.34%","content_offset":["10845","10870"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["5.34%","10865","10870"],"indicator_element":{"行业":["化学原料药","10845","10850"],"时间":["2020年","10852","10857"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长19.91%","content_offset":["10871","10886"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["19.91%","10880","10886"],"indicator_element":{"行业":["化学原料药","10817","10822"],"时间":["2020年","10852","10857"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1原料药板块营业收入同比增长26.37%","content_offset":["10903","10928"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["26.37%","10922","10928"],"indicator_element":{"行业":["原料药","10909","10912"],"时间":["2021Q1","10903","10909"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长17.02%","content_offset":["10929","10944"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["17.02%","10938","10944"],"indicator_element":{"行业":["原料药","10829","10832"],"时间":["2021Q1","10903","10909"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"对比2019Q1营收和净利润年复合增长率分别为9.62%和12.55%","content_offset":["10945","10980"],"indicators":[{"indicator_name":"营业收入","indicator_value":["9.62%","10968","10973"],"indicator_element":{"行业":["原料药","10847","10850"],"时间":["2021Q1","10903","10909"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"对比2019Q1营收和净利润年复合增长率分别为9.62%和12.55%","content_offset":["10945","10980"],"indicators":[{"indicator_name":"净利润年复合增长率","indicator_value":["12.55%","10974","10980"],"indicator_element":{"行业":["原料药","10847","10850"],"时间":["2021Q1","10903","10909"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"原料药板块2020年毛利率提升2.23pct至36.43%","content_offset":["11874","11903"],"indicators":[{"indicator_name":"毛利率","indicator_value":["36.43%","11897","11903"],"indicator_element":{"行业":["原料药","11874","11877"],"时间":["2020年","11879","11884"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"原料药板块2020年毛利率提升2.23pct至36.43%","content_offset":["11874","11903"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["2.23pct","11889","11896"],"indicator_element":{"行业":["原料药","11874","11877"],"时间":["2020年","11879","11884"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1毛利率为35.93%","content_offset":["11938","11954"],"indicators":[{"indicator_name":"毛利率","indicator_value":["35.93%","11948","11954"],"indicator_element":{"行业":["原料药","11874","11877"],"时间":["2021Q1","11938","11944"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年原料药板块净利率提升1.83pct至15.3%","content_offset":["11991","12019"],"indicators":[{"indicator_name":"净利率","indicator_value":["15.3%","12014","12019"],"indicator_element":{"行业":["原料药","11996","11999"],"时间":["2020年","11991","11996"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年原料药板块净利率提升1.83pct至15.3%","content_offset":["11991","12019"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["1.83pct","12006","12013"],"indicator_element":{"行业":["原料药","11996","11999"],"时间":["2020年","11991","11996"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1净利率再微增加0.16pct","content_offset":["12020","12040"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["0.16pct","12033","12040"],"indicator_element":{"行业":["原料药","11970","11973"],"时间":["2021Q1","12020","12026"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"化学制剂板块2020年营收同比下滑6.06%","content_offset":["12167","12189"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下滑6.06%","12182","12189"],"indicator_element":{"行业":["化学原料药","-1","-1"],"时间":["2020年","12173","12178"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长14.33%","content_offset":["12190","12205"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["14.33%","12199","12205"],"indicator_element":{"行业":["化学原料药","-1","-1"],"时间":["2020年","12173","12178"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020Q1化学制剂板块营业收入同比增长15.45%","content_offset":["12225","12251"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["15.45%","12245","12251"],"indicator_element":{"行业":["化学制剂","12231","12235"],"时间":["2020Q1","12225","12231"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长22.15%","content_offset":["12252","12267"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["22.15%","12261","12267"],"indicator_element":{"行业":["化学制剂","12167","12171"],"时间":["2020Q1","12225","12231"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"生物制品板块2020年毛利率为56.74%","content_offset":["14046","14067"],"indicators":[{"indicator_name":"毛利率","indicator_value":["56.74%","14061","14067"],"indicator_element":{"行业":["生物制品","14046","14050"],"时间":["2020年","14052","14057"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比上升1.85个百分点","content_offset":["14068","14080"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["1.85个百分点","14072","14080"],"indicator_element":{"行业":["生物制品","13974","13978"],"时间":["2020年","14052","14057"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020年营业总收入同比下滑2.61%","content_offset":["16271","16290"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下滑2.61%","16283","16290"],"indicator_element":{"行业":["中药","16185","16187"],"时间":["2020年","16271","16276"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比下滑14.65个百分点","content_offset":["16291","16304"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["14.65个百分点","16295","16304"],"indicator_element":{"行业":["中药","16258","16260"],"时间":["2020年","16271","16276"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润增长率11.2%","content_offset":["16305","16318"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["11.2%","16313","16318"],"indicator_element":{"行业":["中药","16258","16260"],"时间":["2020年","16271","16276"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2020Q1中药板块营业收入增长20.02%","content_offset":["16429","16451"],"indicators":[{"indicator_name":"营业收入","indicator_value":["20.02%","16445","16451"],"indicator_element":{"行业":["中药","16435","16437"],"时间":["2020Q1","16429","16435"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润增长19.37%","content_offset":["16452","16465"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["19.37%","16459","16465"],"indicator_element":{"行业":["中药","16435","16437"],"时间":["2020Q1","16429","16435"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"中药板块2020年毛利率为43.39%","content_offset":["16672","16691"],"indicators":[{"indicator_name":"毛利率","indicator_value":["43.39%","16685","16691"],"indicator_element":{"行业":["中药","16672","16674"],"时间":["2020年","16676","16681"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比下降0.99个百分点","content_offset":["16692","16704"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["下降0.99个百分点","16694","16704"],"indicator_element":{"行业":["中药","16604","16606"],"时间":["2020年","16676","16681"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1板块毛利率44.67%","content_offset":["16776","16793"],"indicators":[{"indicator_name":"毛利率","indicator_value":["44.67%","16787","16793"],"indicator_element":{"行业":["中药","16832","16834"],"时间":["2020Q1","17087","17093"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医药商业板块2020年营业总收入增速8.46%","content_offset":["17319","17342"],"indicators":[{"indicator_name":"营业收入","indicator_value":["8.46%","17337","17342"],"indicator_element":{"行业":["医药商业","17319","17323"],"时间":["2020年","17325","17330"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比下滑7.38个百分点","content_offset":["17343","17355"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["下滑7.38个百分点","17345","17355"],"indicator_element":{"行业":["医药商业","17319","17323"],"时间":["2020年","17325","17330"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润增长率7.38%","content_offset":["17356","17369"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["7.38%","17364","17369"],"indicator_element":{"行业":["医药商业","17319","17323"],"时间":["2020年","17325","17330"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1流通板块营业收入上升24.7%","content_offset":["17414","17435"],"indicators":[{"indicator_name":"营业收入","indicator_value":["24.7%","17430","17435"],"indicator_element":{"行业":["流通","17420","17422"],"时间":["2020Q1","17457","17463"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润增长39.11%","content_offset":["17436","17449"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["39.11%","17443","17449"],"indicator_element":{"行业":["流通","17420","17422"],"时间":["2020Q1","17457","17463"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医药商业板块2020年毛利率为13.36%","content_offset":["17660","17681"],"indicators":[{"indicator_name":"毛利率","indicator_value":["13.36%","17675","17681"],"indicator_element":{"行业":["医药商业","17660","17664"],"时间":["2020年","17666","17671"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"同比下降0.32个百分点","content_offset":["17682","17694"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["下降0.32个百分点","17684","17694"],"indicator_element":{"行业":["医药商业","17660","17664"],"时间":["2020年","17666","17671"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1板块毛利率12.57%","content_offset":["17765","17782"],"indicators":[{"indicator_name":"毛利率","indicator_value":["12.57%","17776","17782"],"indicator_element":{"行业":["医药商业","-1","-1"],"时间":["2021Q1","17765","17771"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"IVD板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%","content_offset":["20026","20066"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["59.5%","20054","20059"],"indicator_element":{"行业":["IVD","20026","20029"],"时间":["2020年","20031","20036"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"IVD板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%","content_offset":["20026","20066"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["148.4%","20060","20066"],"indicator_element":{"行业":["IVD","20026","20029"],"时间":["2020年","20031","20036"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为83.5%和216.3%","content_offset":["20067","20096"],"indicators":[{"indicator_name":"营业收入增长率","indicator_value":["83.5%","20084","20089"],"indicator_element":{"行业":["IVD","19997","20000"],"时间":["2021Q1","20067","20073"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为83.5%和216.3%","content_offset":["20067","20096"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["216.3%","20090","20096"],"indicator_element":{"行业":["IVD","19997","20000"],"时间":["2021Q1","20067","20073"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"耗材板块2020年营业总收入和归母净利润同比增速分别为35.5%和120.6%","content_offset":["21014","21053"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["35.5%","21041","21046"],"indicator_element":{"行业":["耗材","21014","21016"],"时间":["2020年","21018","21023"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"耗材板块2020年营业总收入和归母净利润同比增速分别为35.5%和120.6%","content_offset":["21014","21053"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["120.6%","21047","21053"],"indicator_element":{"行业":["耗材","21014","21016"],"时间":["2020年","21018","21023"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为65.1%和237.0%","content_offset":["21054","21083"],"indicators":[{"indicator_name":"营业收入增长率","indicator_value":["65.1%","21071","21076"],"indicator_element":{"行业":["耗材","21014","21016"],"时间":["2021Q1","21054","21060"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为65.1%和237.0%","content_offset":["21054","21083"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["237.0%","21077","21083"],"indicator_element":{"行业":["耗材","21014","21016"],"时间":["2021Q1","21054","21060"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"设备板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%","content_offset":["21809","21848"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["59.5%","21836","21841"],"indicator_element":{"行业":["设备","21809","21811"],"时间":["2020年","21813","21818"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"设备板块2020年营业总收入和归母净利润同比增速分别为59.5%和148.4%","content_offset":["21809","21848"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["148.4%","21842","21848"],"indicator_element":{"行业":["设备","21809","21811"],"时间":["2020年","21813","21818"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为83.5%和216.3%","content_offset":["20067","20096"],"indicators":[{"indicator_name":"营业收入增长率","indicator_value":["83.5%","20084","20089"],"indicator_element":{"行业":["设备","21784","21786"],"时间":["2021Q1","20067","20073"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1营收和净利润增速分别为83.5%和216.3%","content_offset":["20067","20096"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["216.3%","20090","20096"],"indicator_element":{"行业":["设备","21784","21786"],"时间":["2021Q1","20067","20073"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医疗服务板块2020年营业收入增长14.68%","content_offset":["22587","22610"],"indicators":[{"indicator_name":"营业收入","indicator_value":["14.68%","22604","22610"],"indicator_element":{"行业":["医疗服务","22587","22591"],"时间":["2020年","22593","22598"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"归母净利润同比增长965%","content_offset":["22611","22624"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["965%","22620","22624"],"indicator_element":{"行业":["医疗服务","22511","22515"],"时间":["2020年","22593","22598"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"总营收和净利润对比2019Q1年复合增长率分别为24.98%和72.92%","content_offset":["22747","22784"],"indicators":[{"indicator_name":"营业收入年复合增长率","indicator_value":["24.98%","22771","22777"],"indicator_element":{"区域":["国内","22711","22713"],"行业":["医疗服务","22735","22739"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"总营收和净利润对比2019Q1年复合增长率分别为24.98%和72.92%","content_offset":["22747","22784"],"indicators":[{"indicator_name":"净利润年复合增长率","indicator_value":["72.92%","22778","22784"],"indicator_element":{"区域":["国内","22711","22713"],"行业":["医疗服务","22735","22739"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医疗服务板块2020年毛利率减少0.05pct至38.16%","content_offset":["22976","23006"],"indicators":[{"indicator_name":"毛利率","indicator_value":["38.16%","23000","23006"],"indicator_element":{"行业":["医疗服务","22976","22980"],"时间":["2020年","22982","22987"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"医疗服务板块2020年毛利率减少0.05pct至38.16%","content_offset":["22976","23006"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["减少0.05pct","22990","22999"],"indicator_element":{"行业":["医疗服务","22976","22980"],"时间":["2020年","22982","22987"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1毛利率降低2.14个百分点到36.02%","content_offset":["23014","23040"],"indicators":[{"indicator_name":"毛利率","indicator_value":["36.02%","23034","23040"],"indicator_element":{"行业":["医疗服务","22923","22927"],"时间":["2021Q1","23014","23020"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"2020年年报、2021Q1季报小结及前瞻：业绩恢复强劲，高景气赛道表现亮眼.pdf","content":"2021Q1毛利率降低2.14个百分点到36.02%","content_offset":["23014","23040"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["降低2.14个百分点","23023","23033"],"indicator_element":{"行业":["医疗服务","22923","22927"],"时间":["2021Q1","23014","23020"]},"indicator_supplement":{"属性":""}}]}]}